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OBJECTIVES: Previous research has shown that untreated
insomnia has signiﬁcant direct and indirect burden. The lifetime
prevalence of major depressive disorder (MDD) is more than
17%, with up to 80% reporting comorbid insomnia. The
purpose of this study was to estimate the economic burden of
comorbid untreated insomnia within an adult depressed popula-
tion. METHODS: A large managed care claims database was
used to identify MDD subjects (18 to 64 years) anytime between
January 1, 1998 to November 30, 2007 using MDD-speciﬁc
ICD-9-CM diagnoses. Depressed insomniacs were selected from
this cohort using insomnia-speciﬁc ICD-9-CM codes/hypnotic-
use. Direct costs were compared with a 1:1 matched control
group that had depression and no insomnia vs. depressed-
insomniacs twelve-months prior to initiating insomnia treatment/
diagnosis. Total direct costs included inpatient, outpatient, ER
and drug costs. Multivariate regression analyses were conducted
to control for factors that were different even after matching.
Cost outcomes were analyzed using log-transformation and then
retransformed to their original scale after applying smearing
factor. All statistical tests were conducted using SAS 9.1.
RESULTS: A total of 41,594 controls were matched to 41,594
depressed-insomniacs on demographic characteristics, index-
date, antidepressant use, plan type, and region using propensity-
scoring technique. Depressed-insomniacs had statistically greater
(p < 0.01) total outpatient visits 9.24 (SD = 10.14) vs control
7.92 (SD = 8.42); depression-related visits 4.32 (SD = 8.33) vs
control 2.36 (SD = 5.32); and antidepressant prescriptions 5.28
(SD = 5.92) vs control 4.71 (SD = 5.27). Overall total direct costs
for depressed-insomniacs were signiﬁcantly (p < 0.001) higher
than controls ($6,772 vs. $5,644) after matching and controlling
for differences in age, location, plan-type, index year, and comor-
bidity patterns. The $1128 difference in average medical expen-
diture reﬂected the estimate of direct cost of untreated insomnia
in adult depressed population. CONCLUSIONS:Untreated
insomnia within an adult comorbid depressed population is asso-
ciated with signiﬁcant direct costs. Future research needs to
determine whether treating comorbid-insomnia with MDD
population is cost-effective.
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OBJECTIVES: Previous research has shown that untreated
insomnia within the elderly has signiﬁcant economic burden. The
lifetime prevalence of major depressive disorder (MDD) is more
than 17%, of which up to 80% have comorbid insomnia. The
purpose of this study was to estimate the economic burden of
untreated insomnia within an elderly comorbid depressed popu-
lation. METHODS: A large managed care claims database was
used to identify elderly MDD subjects between January 1, 1998
to November 30, 2007 using MDD-speciﬁc ICD-9-CM codes.
Depressed insomniacs were selected from this cohort using
insomnia-speciﬁc ICD-9-CM codes/hypnotic-use. Direct costs
were compared with a 1:1 matched control group that had
depression and no insomnia vs. depressed-insomniacs twelve-
months prior to initiating insomnia treatment/diagnosis. Total
direct costs included inpatient, outpatient, ER and drug costs.
Multivariate regression analyses were conducted to control for
factors that were different even after matching. Cost outcomes
were log-transformed and then retransformed to their original
scale after applying smearing factor. All statistical tests were
conducted using SAS 9.1. RESULTS: A total of 2900 controls
were matched to 2900 depressed-insomniacs on demographic
characteristics, index-date, antidepressant use, plan type,
and region using propensity-scoring technique. Depressed-
insomniacs had higher (p < 0.001) total outpatient visits 11.20
(SD = 10.32) vs control 8.71 (SD = 7.32); depression-related
visits 4.05 (SD = 8.41) vs control 1.70 (SD = 3.27);
antidepressant-use 3.39 (SD = 5.18) vs control 2.87 (SD = 4.51).
Overall total direct costs for depressed-insomniacs were signiﬁ-
cantly (p < 0.001) higher than controls ($9835 vs. $8384) after
matching and controlling for differences in age, location, plan-
type, index year, and comorbidity patterns. The $1451 difference
in average medical expenditure per-subject reﬂected the estimate
of direct cost of untreated insomnia in an elderly depressed
population. CONCLUSIONS: Untreated insomnia within an
elderly comorbid depressed population is associated with signiﬁ-
cant direct costs. Future research needs to determine prevalence
and cost-effectiveness of treating comorbid insomnia within this
population.
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OBJECTIVES: To analyse the economic impact of one-year
health care and non-health care resources utilization by patients
with Alzheimer disease (AD) under usual medical practice con-
ditions in Spain. METHODS: A one-year, prospective, natural-
istic, multicentre cohort study was designed to recruit treated
patients with mild, moderate to severe and severe AD according
to CDR: the ECO study. Health care resources included all kind
of medical visits, drugs and concomitant treatments, comple-
mentary tests, institutionalization and home-nursing facilities’
use. Non-health care resources included inventory materials,
consumables, professional and non-professional carers’ time of
care and supervision. Results were analysed according to
patients’ socio-demographic data, degree of AD (CDR; MMSE
and BDRS), overall health status (HUI3), and to variables inher-
ent to the main carer including hours of care and supervision
and health status (HUI3) and stress (Zarit). RESULTS: A total
of 560 patients with possible/probable AD by DSM-IV-
NINCDS-ADRDA criteria were included in the study; 68%
women, 77  6 years old, 29% treatment naïve. Monthly mean
cost was €1,078 (€12,936 patient/ year), increasing by 9.4% at
the end of the study from a baseline cost of €993. By compo-
nents, non-health care costs (€760, 71% of total cost) decreased
€7 (0.8%) at the end of the year, while health care costs grew
€101/month (43.9%), mainly driven by the cost of drugs,
nursing home utilization and institutionalization. The 82% of
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